Phase II Study of Lenvatinib in Recurrent or Metastatic Adenoid Cystic Carcinoma
Posted: Friday, April 26, 2019
In a phase II study of lenvatinib in patients with progressive, recurrent or metastatic adenoid cystic carcinoma, 15.6% partially responded and 75% had stable disease. However, more than half patients stopped taking lenvatinib because of “drug-related issues.” These results were published in the Journal of Clinical Oncology.
The open-label study, conducted by Vatche Tchekmedyian, MD, MEd, and researchers at Memorial Sloan Kettering Cancer Center, focused on 32 patients with recurrent or metastatic adenoid cystic carcinoma—a rare form of cancer commonly arising in the salivary glands. The patients, who were between the ages of 38 and 73, were each given 24 mg of lenvatinib, orally per day.
A total of 5 patients had a partial response, 24 patients had stable disease, and the median progression-free survival was 17.5 months. Most patients (66%) experienced tumor regression, whereas one patient had progression of disease. Five patients were removed from the trial due to toxicity; nine withdrew their consent, and a further six were removed at the discretion of their physician. Adverse side effects included hypertension and oral pain.
“This trial met the prespecified overall response rate primary endpoint, demonstrating antitumor activity with lenvatinib in [patients with recurrent or metastatic adenoid cystic carcinoma],” the investigators said. “Toxicity was comparable to previous studies, requiring monitoring and management.”
Disclosure: The study author disclosures may be found at ascopubs.org.